Pharmaceuticals

Peanut Allergy Treatment Market Size and Growth Forecast for Businesses 2025–2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Peanut Allergy Treatment Market?

The peanut allergy treatment market size has seen rapid growth in recent years. It is projected to increase from $0.45 billion in 2024 to $0.5 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.4%. The expansion observed historically is due to factors including increased prevalence, advancements in diagnostic testing, growing public awareness and concern, the development of early intervention strategies, and regulatory approvals for peanut allergy treatments.

The peanut allergy treatment market is projected to experience significant expansion over the coming years. This market is anticipated to reach “$0.74 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.2%. Contributing factors to this growth during the forecast period include the ongoing increase in prevalence, the development of personalized medicine strategies, the emergence of new immunotherapy options, increased public and private funding, and the broadening of telemedicine services. Key trends anticipated for the forecast period encompass a greater uptake of immunotherapy, progress in biologic treatments, the incorporation of probiotic-derived therapies, technological breakthroughs in delivery mechanisms, individualized medicine techniques, and favorable regulatory endorsements.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp

What Are The Main Drivers Boosting The Peanut Allergy Treatment Industry’s Expansion?

The peanut allergy treatment market is expected to grow due to ongoing investment in the research and development of allergy treatments. Research and development (R&D) investment involves the financial resources allocated by companies, organizations, or governments towards activities focused on innovation, product creation, and technological advancement. Investment in allergy treatment R&D is vital for developing better peanut allergy therapies. This funding supports the creation of new immunotherapies and desensitization techniques, which aim to lessen allergic reactions and improve the quality of life for individuals affected by peanut allergies. For instance, in January 2024, the Victorian Government announced a strategic $12 million investment in Aravax, an Australia-based clinical-stage biotechnology company, to significantly advance global peanut allergy treatment. This funding forms part of a broader $66 million round intended for developing Aravax’s innovative immunotherapy, PVX108. This program has received Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), underscoring its potential impact on public health worldwide. Therefore, investment in the research and development of allergy treatments is a key driver for the growth of the peanut allergy treatment market.

What Are The Key Segments In The Peanut Allergy Treatment Market?

The peanut allergy treatment market covered in this report is segmented –

1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes

2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:

1) By Antihistamines: Oral Antihistamines, Topical Antihistamines

2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)

3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers

4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids

Which Trends Are Impacting The Peanut Allergy Treatment Market?

Leading companies within the peanut allergy treatment market are prioritizing the creation of biologic therapies, specifically anti-IgE monoclonal antibodies. This focus aims to deliver more precise and potent solutions for managing peanut allergies, thereby enhancing patient outcomes and overall quality of life. These anti-IgE monoclonal antibodies represent a class of therapeutic agents engineered to pinpoint and neutralize immunoglobulin E (IgE) antibodies within the body. An illustrative example occurred in February 2024, when Novartis Pharmaceuticals Corporation, a pharmaceutical firm based in Switzerland, secured approval from the Food and Drug Administration (FDA) for its product, Xolair (omalizumab). This particular medication is intended to diminish allergic reactions, including severe anaphylaxis, for patients 1 year and older experiencing IgE-mediated food allergies. The basis for this approval was data derived from the NIH-sponsored Phase III OUtMATCH study, which demonstrated a notable improvement in food allergy tolerance among individuals administered Xolair when contrasted with those given a placebo.

Which Leading Players Are Enhancing Their Peanut Allergy Treatment Market Presence Worldwide?

Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd., Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

What Are The Regional Market Dynamics Impacting The Peanut Allergy Treatment Industry?

North America was the largest region in the peanut allergy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Peanut Allergy Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15888&type=smp

Browse Through More Reports Similar to the Global Peanut Allergy Treatment Market 2025, By The Business Research Company

Merkel Cell Carcinoma Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/merkel-cell-carcinoma-treatment-global-market-report

Basal Cell Carcinoma Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/basal-cell-carcinoma-treatment-global-market-report

Crohns Disease Cd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795